Doctor says GLP‑1s may reduce inflammation
Dr. Sue Decotiis, a New York City weight‑loss physician, tells Fox News that GLP‑1 receptor agonists (including Ozempic, Wegovy, Mounjaro and Zepbound) may do more than promote weight loss — reducing adipose‑driven inflammatory cytokines and potentially lowering incidence of chronic diseases from arthritis to cardiovascular disease and cancer. The article cites recent research (including a Swiss projection estimating a 6.4% reduction in annual deaths by 2045) and includes the doctor's prescribing guidance urging patients to consult certified weight‑loss physicians rather than self‑dosing.
Health
Science
📰 Sources (1)
Weight-loss doctor shares how GLP-1s could rewire body against disease
New information:
- Interview subject: Dr. Sue Decotiis, NYC board‑certified weight‑loss physician, discusses systemic effects of GLP‑1s
- Drug specifics: references semaglutides (Ozempic, Wegovy) and tirzepatides (Mounjaro, Zepbound) as example GLP‑1 agents
- Research/data: cites a Swiss study projecting a 6.4% reduction in the annual death rate by 2045 associated with broader GLP‑1 use